上海
埃萬(wàn)妥單抗聯(lián)合治療方案為不同EGFR突變晚期NSCLC人群提供精準(zhǔn)治療選擇。
*以下內(nèi)容僅供醫(yī)療衛(wèi)生專(zhuān)業(yè)人士瀏覽。
參考文獻(xiàn)：
[1] 中華醫(yī)學(xué)會(huì)腫瘤學(xué)分會(huì). 中華醫(yī)學(xué)會(huì)肺癌臨床診療指南（2025版）[J]. 中華腫瘤雜志, 2025, 47(9): 769-810.
[2] Boustany Y, et al. Prevalence and Patterns of EGFR Mutations in Non-small Cell Lung Cancer in the Middle East and North Africa. Cancer Control. 2022;29: 1-9.
[3] Zhou C, et al. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med. 2023 Nov 30;389(22):2039-2051.
[4] Zhou C. et al. Amivantamab plus chemotherapy vs chemotherapy as a first-line treatment among Asian patients with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): PAPILLON subgroup analysis. 2023 ESMO Asia.513MO.
[5]Cho BC, et al. Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. N Engl J Med. 2024 Oct 24;391(16):1486-1498.
[6]Yang JC, et al. MARIPOSA Investigators. Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2025 Sep 7.
[7]Lu S, et al. Amivantamab Plus Lazertinib vs Osimertinib as First-line Treatment Among Asian Patients With EGFR-mutated, Advanced Non-small Cell Lung Cancer (NSCLC): MARIPOSA Subgroup Analysis. 2023 ESMO Aisa. LBA10.
審批編碼：CP-558517
批準(zhǔn)分發(fā)日期：12/16/2025
有效期：12/16/2026
*“醫(yī)學(xué)界”力求所發(fā)表內(nèi)容專(zhuān)業(yè)、可靠，但不對(duì)內(nèi)容的準(zhǔn)確性做出承諾；請(qǐng)相關(guān)各方在采用或以此作為決策依據(jù)時(shí)另行核查。
特別聲明：以上內(nèi)容(如有圖片或視頻亦包括在內(nèi))為自媒體平臺(tái)“網(wǎng)易號(hào)”用戶(hù)上傳并發(fā)布，本平臺(tái)僅提供信息存儲(chǔ)服務(wù)。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.
